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Abstract
Introduction: People infected with human immunodeficiency virus are frequently treated with
medications that can induce or inhibit cytochrome P450 enzymes.
Case presentation: A 59 year old man treated with zidovudine, lamivudine, indinavir, and
ritonavir for infection with human immunodeficiency virus volunteered to take part in a study of
bone loss. He was found to have vitamin D insufficiency with secondary hyperparathyroidism and
received vitamin D and calcium supplementation. He suffered a recurrence of infection with
Mycobacterium avium intracellulare for which he received treatment with ciprofloxacin, rifabutin, and
ethambutol. Subsequently, he developed worsening vitamin D deficiency with hypocalcaemia,
secondary hyperparathyroidism and elevated markers of bone turnover culminating in an
osteomalacic vertebral fracture. Correction of the vitamin D deficiency required 100,000 IU of
cholecalciferol monthly.
Rifabutin is a cytochrome P450 inducer, and vitamin D and its metabolites are catabolised by
cytochrome P450 enzymes. We therefore propose that treatment with rifabutin led to the
induction of cytochrome P450 enzymes catabolising vitamin D, thereby causing vitamin D
deficiency and osteomalacia. This process might be mediated through the steroid and xenobiotic
receptor (SXR).
Conclusion: Treatment with rifabutin induces the cytochrome P450 enzymes that metabolise
vitamin D and patients treated with rifabutin might be at increased risk of vitamin D deficiency. In
complex medication regimens involving agents that induce or inhibit cytochrome P450 enzmyes,
consultation with a clinical pharmacist or pharmacologist may be helpful in predicting and/or
preventing potentially harmful interactions.
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Introduction
Medications that induce or inhibit cytochrome P450
enzymes are commonly prescribed and therefore drug
interactions mediated by changes in these enzymes are
also common. People infected with human immunodefi-
ciency virus (HIV) are frequently treated with complex
medical regimens containing a number of medications
that can induce or inhibit cytochrome P450 enzymes. We
present a case of osteomalacia in an HIV-infected man
that was likely caused by cytochrome P450-mediated
alterations in vitamin D metabolism.
Case presentation
A 59 year old Sri Lankan man volunteered to take part in
a clinical study of bone loss in men infected with HIV. He
had been diagnosed with HIV infection five years earlier.
He also had a history of bronchiectasis and infection with
Mycobacterium avium intracellulare (MAIC). He had been
treated with zidovudine, lamivudine and indinavir for
four years. Ritonavir 100 mg twice daily was added two
years earlier. Ritonavir is a potent cytochrome P450 inhib-
itor that inhibits the metabolism of indinavir allowing it
to be taken in smaller doses at less frequent intervals [1].
He also was taking clarithromycin and ethambutol for
MAIC prophylaxis and cotrimoxazole for Pneumocystis
jiroveci prophylaxis. His CD4 count was 41 cells/μL and
viral load undetectable at time of study entry. Both param-
eters had been stable at these levels for more than 12
months prior to study entry.
Biochemical tests at the time of study entry and subse-
quently are shown in Figure 1. At the baseline visit he had
vitamin D deficiency [25-hydroxyvitamin D (25OHD)
<25 nmol/L] [2] with secondary hyperparathyroidism and
a raised alkaline phosphatase (ALP). Liver and kidney
function were normal. Bone mineral density (BMD) at the
total hip was measured with a Lunar Expert dual energy x-
ray absorptiometer and was 0.613 g/cm2. He subse-
quently received 400 mg calcium daily and 50,000 IU
vitamin D (cholecalciferol) monthly. After four months
his 25OHD level had increased although it was still below
the recommended level of 50 nmol/L [2]. The secondary
hyperparathyroidism and elevated ALP persisted.
After 14 months he developed recurrence of MAIC infec-
tion, and treatment was commenced with ciprofloxacin,
rifabutin, and ethambutol. Blood tests at this time
showed normalisation of ALP but a low 25OHD level
(Figure 1) despite reported full compliance with medica-
tion. Over the next nine months his blood tests showed
worsening vitamin D deficiency, development of hypocal-
caemia, secondary hyperparathyroidism, and progressive
elevation of ALP. After 21 months, he developed lower
back pain and generalised myalgia. Magnetic resonance
imaging showed a fracture of the endplate of L1. His
symptoms and biochemical tests were consistent with
osteomalacia although confirmatory bone biopsy was not
performed. BMD at the total hip decreased by 17%
between 12 and 23 months.
When the diagnosis of osteomalacia was recognised at 23
months, he was treated with a loading dose of 600,000 IU
of cholecalciferol and thereafter 100,000 IU per month,
and 1 g of calcium daily. This produced a rapid normali-
sation of his serum calcium, phosphate, ALP and 25OHD,
and resolution of the musculoskeletal symptoms,
although serum parathyroid hormone remained mildly
elevated.
Discussion
Vitamin D insufficiency (25OHD <50 nmol/L) [2] is com-
mon in adults, especially in the elderly, and causes myop-
athy, osteopenia, secondary hyperparathyroidism, and
osteomalacia [3,4]. The prevalence of osteomalacia in
adults is unknown but is thought to be rare outside high
risk groups such as the frail elderly [4].
The major source of vitamin D is from photolysis of ster-
oid precursors in the skin, with only a small dietary con-
tribution. Vitamin D is then hydroxylated in the liver to
25OHD by a cytochrome P450 enzyme called 25-hydrox-
ylase. 25OHD is further hydroxylated in the kidney by a
cytochrome p450 enzyme, 1α-hydroxylase, to 1,25-dihy-
droxyvitamin D [1,25(OH)2D], the most active form of
vitamin D. Other cytochrome P450 enzymes such as 24-
hydroxylase metabolise the hydroxylated forms of vita-
min D to inactive metabolites which are excreted in the
bile. Each of these cytochrome P450 enzymes can be stim-
ulated or inhibited by medication (Figure 2).
Our patient was treated with a number of medications
that influence cytochrome P450 enzymes. At study entry
he was treated with ritonavir, indinavir and clarithromy-
cin – all cytochrome P450 inhibitors – and later he
received rifabutin, a cytochrome P450 stimulator. Ritona-
vir is a potent cytochrome P450 inhibitor that has differ-
ential effects on vitamin D hydroxylase enzymes. In vitro,
it is a potent inhibitor of both 1α-hydroxylase and 25-
hydroxylase and a weak inhibitor of 24-hydroxylase. Thus
it would be predicted in vivo, to lower levels of both
25OHD and 1,25(OH)2D [5]. Indinavir is a weaker cyto-
chrome P450 inhibitor and would be predicted to have
similar but lesser effects [5]. The effects of ritonavir and
indinavir on vitamin D metabolism are expected to be
similar to those described with isoniazid, another cyto-
chrome P450 inhibitor [6]. Clarithromycin is a cyto-
chrome P450 inhibitor that appears to be a less potent
inhibitor than erythromycin [7]. Neither clarithromycin
nor erythromycin has been reported to affect vitamin DAnnals of Clinical Microbiology and Antimicrobials 2008, 7:3 http://www.ann-clinmicrob.com/content/7/1/3
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Panel A show the changes over time in adjusted serum calcium and serum phosphate, Panel B the changes in 25-hydroxyvita- min D (25OHD) and parathyroid hormone (PTH) and Panel C the changes in alkaline phosphatase Figure 1
Panel A show the changes over time in adjusted serum calcium and serum phosphate, Panel B the changes in 25-hydroxyvita-
min D (25OHD) and parathyroid hormone (PTH) and Panel C the changes in alkaline phosphatase. Monthly doses of cholecal-
ciferol are indicated at the top of each panel. Treatment with rifabutin for infection with MAIC started at month 14. Reference 
ranges are indicated by the shaded boxes: adjusted serum calcium 2.10–2.55 mmol/L; phosphate 0.70–1.50 mmol/L; alkaline 
phosphatase 40–120 IU/L; parathyroid hormone 1.7–7.3 pmol/L.Annals of Clinical Microbiology and Antimicrobials 2008, 7:3 http://www.ann-clinmicrob.com/content/7/1/3
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metabolism in vivo, but effects similar to those described
with ritonavir and isoniazid would be predicted.
Rifabutin is a cytochrome P450 inducer that is structurally
similar to rifampicin, but a less potent enzyme stimulator
[8]. The effects of rifabutin on vitamin D metabolism have
not been reported but a two week course of rifampicin was
reported to lower 25OHD levels by 70% in eight young
men without altering levels of 1,25(OH)2D or parathy-
roid hormone [9]. The effects of rifampicin on the indi-
vidual vitamin D hydroxylases have not been reported.
While osteomalacia is well known to occur with the use of
anticonvulsants, which are potent inducers of catabolic
vitamin D hydroxylases, osteomalacia does not appear to
be common with use of rifampicin and isoniazid [10].
Emerging evidence suggests that the orphan nuclear recep-
tor, steroid and xenobiotic receptor (SXR), may have a key
role in the development of drug-induced osteomalacia
[11,12]. Drugs such as rifampicin bind to SXR, which
Schematic diagram of vitamin D metabolism and cytochrome P450 mediated drug effects Figure 2
Schematic diagram of vitamin D metabolism and cytochrome P450 mediated drug effects. Cytochrome P450 enzyme inhibition 
is indicated by broken lines and stimulation by solid lines. The strength of enzyme inhibition or stimulation is indicated by the 
width of the lines and the number of terminal plus or minus signs. As the differential effects of rifabutin on the vitamin D 
hydroxylase enzymes have not been reported, our prediction of the action of rifabutin is shown, which might be mediated by 
SXR. Ritonavir also can bind to SXR which might induce 24-hydroxylase activity, but in vitro ritonavir appears to inhibit rather 
than stimulate 24-hydroxylase. Abbreviations: 7DHC 7-dehydrocholesterol; 25OHase 25-hydroxylase; 25OHD3 25-hydroxyvi-
tamin D3; 1OHase 1α-hydroxylase; 1,25(OH)2D3 1,25-dihydroxyvitamin D3; VDR vitamin D receptor; 24OHase 24-hydroxy-
lase; SXR steroid and xenobiotic receptor.Annals of Clinical Microbiology and Antimicrobials 2008, 7:3 http://www.ann-clinmicrob.com/content/7/1/3
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stimulates 24-hydroxylase activity (Figure 2) thereby caus-
ing increased clearance of vitamin D metabolites, vitamin
D deficiency and osteomalacia. Because of its structural
similarities to rifampicin, rifabutin may also bind to SXR,
although such an interaction has not yet been described.
Protease inhibitors can also bind to SXR but have variable
ability to activate its target genes, with ritonavir but not
indinavir able to activate SXR-regulated pathways [13].
Our patient had vitamin D insufficiency at entry to the
study, a relatively common finding in immigrants or
native-born people with darkly pigmented skin in New
Zealand [14]. Despite vitamin D replacement in doses
that would usually promote adequate levels of 25OHD,
he did not become vitamin D sufficient. This may have
been due to ritonavir, indinavir and clarithromycin medi-
ated inhibition of the cytochrome P450 enzymes that reg-
ulate generation of biologically active vitamin D. Poor
compliance may have also contributed, although the
patient reported taking all his medication. Another possi-
bility is that conversion of 25OHD to 1,25(OH)2D by
activated macrophages in MAIC-related granulomata may
have lowered 25OHD levels. Subsequently, the addition
of rifabutin was followed by the rapid development of
osteomalacia, presumably due to cytochrome P450
enzyme induction that favoured catabolism of 25OHD.
Treatment with doses of cholecalciferol, equivalent to
3,300 IU/day, was required to achieve levels of 25OHD
that enabled normalisation of serum calcium, phosphate
and ALP.
Conclusion
In conclusion, this case demonstrates the importance of
medication-induced alterations in cytochrome P450
enzymes involved in vitamin D metabolism. Patients with
HIV infection often are at risk of opportunistic infections,
or reactivation of tuberculosis infection. In these situa-
tions complex treatment regimens are used which often
involve multiple agents that are capable of affecting cyto-
chrome P450 enzymes. Clinicians need to be aware of
potential cytochrome P450 interactions, and in complex
medication regimens, consultation with a clinical phar-
macist or pharmacologist may be helpful in predicting
and/or preventing potentially harmful interactions.
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